Answers are grounded in this paper and cite their sources.
Background The treatment landscape of adult immune thrombocytopenia (ITP) is increasingly complex, and the relative clinical efficacy of currently available initial combination therapies and subsequent treatment regimens remains unclear. Objective This network meta-analysis was conducted to compare the relative efficacy of first-line and subsequent treatment regimens and to establish a probabilistic ranking of therapeutic strategies for immune thrombocytopenia (ITP). Methods We systematically searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing two or more first-line and subsequent interventions in adults with ITP. Two reviewers independently extracted data and assessed the risk of bias using Cochrane RoB 2.0. Statistical analyses were performed using the R package “netmeta”. Odds ratios and 95% confidence intervals were calculated. Results Nine RCTs with 1, 260 participants and seven interventions were included for first-line treatment comparisons. Within this network analysis, high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO) demonstrated favourable overall response and complete response rates. HD-DXM plus oseltamivir had a higher overall response rate compared with HD-DXM monotherapy. Prednisone (1 mg/kg) plus mycophenolate mofetil (MMF) showed the most favourable profile for 6-month sustained response. For subsequent-line treatment, this study included 28 RCTs comprising 3, 087 patients with chronic, relapsed, or refractory ITP. Twenty-two therapeutic regimens and placebo were evaluated. The results demonstrated that thrombopoietin receptor agonists (TPO-RAs), particularly avatrombopag, romiplostim, rhTPO, and hetrombopag, occupied a dominant position in ITP treatment. Several novel targeted agents showed promising therapeutic potential; however, validation via additional high-quality RCTs is warranted. Conclusion These findings provide preliminary evidence that may help guide individualized selection of first-line and subsequent therapy for adult patients with primary ITP. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261484007 , identifier CRD420261484007.
No takes yet. Share an insight, caveat, or question.
刘安贵 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: